Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2001 Aug;49(8):1025-31.
doi: 10.1046/j.1532-5415.2001.49204.x.

Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population

Affiliations
Clinical Trial

Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population

P H Peters Jr et al. J Am Geriatr Soc. 2001 Aug.

Erratum in

  • J Am Geriatr Soc. 2013 Mar;61(3):478

Abstract

Objectives: To investigate the efficacy of once-daily oral oseltamivir for 6 weeks (Tamiflu) in prophylaxis against laboratory-confirmed clinical influenza in frail older subjects living in homes for seniors and to determine the safety and tolerability of long-term oseltamivir.

Design: Double-blind, placebo-controlled, parallel-group, randomized, multicenter study.

Setting: Thirty-one residential homes for seniors across United States and Europe.

Participants: Five hundred forty-eight frail older occupants (mean age 81 years, >80% vaccinated).

Intervention: Prophylaxis with oseltamivir 75 mg or placebo once daily for 6 weeks, beginning when influenza was detected locally.

Measurements: The primary efficacy endpoint was laboratory-confirmed clinical influenza.

Results: Oseltamivir administration resulted in a 92% reduction in the incidence of laboratory-confirmed clinical influenza compared with placebo (placebo 12/272 (4.4%), oseltamivir 1/276 (0.4%); P = .002). Of subjects vaccinated against influenza, oseltamivir was 91% effective in preventing laboratory-confirmed clinical influenza (placebo 11/218 (5.0%), oseltamivir 1/222 (0.5%); P = .003). Oseltamivir use was associated with a significant reduction in the incidence of secondary complications (placebo 7/272 (2.6%), oseltamivir 1/276 (0.4%); P = .037). Although nearly all subjects were taking concomitant medication both before and during the study, oseltamivir was well tolerated. A similar incidence of adverse events, including gastrointestinal effects, occurred in both groups. There was no suppression of antibody response in oseltamivir recipients.

Conclusion: Oral oseltamivir 75 mg once daily for 6 weeks effectively prevented clinical influenza in vaccinated frail older subjects using significant concomitant medications in a residential care setting. The treatment was well tolerated and provided additional protection to that afforded by vaccination.

PubMed Disclaimer

Comment in

Publication types

LinkOut - more resources